Compare Amphastar Pharmaceuticals Inc (AMPH) vs CleanSpark Inc (CLSK) Price & Performance

AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.

Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.

CleanSpark (CLSK) trades at $12.30, down 3.53% amid a bearish technical outlook despite unanimous analyst buy ratings. The stock faces fundamental challenges with four consecutive quarterly earnings misses and negative profitability margins (-146.9% net income margin). Recent developments include a strategic pivot toward AI data centers, highlighted by a 20-year, $6.6 billion lease agreement in Sandersville, Georgia, which aims to diversify revenue streams beyond Bitcoin mining.

The stock presents a high-risk, high-reward opportunity with analysts projecting 94% upside to a $23.89 consensus target. Key risks include persistent earnings underperformance, negative cash flow from operations, and execution challenges in the AI infrastructure transition. Investors must weigh the long-term potential of the data center pivot against near-term financial volatility and dilution concerns.